Most strains of gonorrhea are now resistant to penicillins, tetracyclines, spectinomycin, narrow-spectrum cephalosporins, amphenicols, sulfonamide and trimethoprim combinations, and fluoroquinolones (abandoned in treatment guidelines as recently as 2007).
For gonorrhea infections in the U.S., we're down to the last of the most effective & curative single-therapy antibiotics, which have shown decreasing susceptibility recently. Treatment recommendations now include a combo of a broad-spectrum cephalosporin along with azithromycin. Using dual-therapy temporarily helps slow progression of resistance.
However, within the past decade, extensively drug-resistant gonorrhea demonstrating treatment failure to all 3rd-generation cephalosporins have been reported in Japan, France, and Spain (countries from 5 continents have reported resistance to at least one of the 3rd-gen cephalosporins).
Rare cases of gonorrhea with high-level resistance to azithromycin emerged a few years ago. (Resistance to azithro occurs fairly easily, so it's not supposed to be given by itself.)
I think the mortality rate after infection with carbapenemase-positive Klebsiella pneumoniae is something near 50% (can't remember if that's in general or site-specific, like in lungs vs. bones, or just in a particular region of the world).
I'm guessing the quote at the end about these events already happening seemingly "mostly far away from us" probably refers to Africa and Asia. Multi-drug resistant TB has been a global problem for quite some time.
Many people might start to realize we take a lot of things for granted in the U.S....